Laura Raykowski
Primary Care · Montesano, WANPI 1407924566
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 163 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 27 manufacturers, the largest accounting for just 17.9% — the pattern of someone who eats at a lot of different presentations. Among primary care clinicians in WA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 163 payments — averaging $19.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$561
- Bayer$444
- AbbVie$387
- Novo Nordisk$175
- Alkermes, Inc.$150
- Kowa Pharmaceuticals America, Inc.$137
- plus $1K from 21 others
What the payments were for
- Food & beverage$3,125100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 29 | $561 |
| Bayer | 16 | $444 |
| AbbVie | 27 | $387 |
| Novo Nordisk | 9 | $175 |
| Alkermes, Inc. | 7 | $150 |
| Kowa Pharmaceuticals America, Inc. | 8 | $137 |
| Pfizer | 7 | $129 |
| Otsuka America Pharmaceutical, Inc. | 6 | $129 |
| Sanofi-aventis U.S. LLC | 6 | $126 |
| Lundbeck LLC | 4 | $103 |
| Lilly USA, LLC | 6 | $103 |
| GSK | 5 | $94 |
| Exact Sciences | 5 | $90 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 4 | $81 |
| Xeris Pharmaceuticals, Inc. | 4 | $69 |
| Boehringer Ingelheim | 3 | $55 |
| Amgen | 3 | $50 |
| Teva Pharmaceuticals USA, Inc. | 2 | $42 |
| Harmony Biosciences LLC | 2 | $32 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $31 |
| Mylan Specialty L.p. | 2 | $31 |
| Tandem Diabetes Care, Inc. | 1 | $23 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $20 |
| Phadia US Inc. | 1 | $20 |
| Viatris Specialty LLC | 1 | $18 |
| Phathom Pharmaceuticals, Inc. | 1 | $14 |
| Abbott | 1 | $13 |
How this compares
$3,125 in reported general payments places this provider in the 90th percentile of 94 primary care providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 86 | $104,136 |
| EliquisApixaban | 77 | $74,696 |
| VraylarCariprazine Hcl | 40 | $70,347 |
| JardianceEmpagliflozin | 59 | $60,456 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 72 | $52,832 |
| FarxigaDapagliflozin Propanediol | 48 | $52,409 |
| TrulicityDulaglutide | 43 | $50,075 |
| MounjaroTirzepatide | 25 | $28,785 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 45 | $26,750 |
| Nurtec OdtRimegepant Sulfate | 13 | $25,555 |
| Breo ElliptaFluticasone/Vilanterol | 24 | $10,144 |
| Humalog Kwikpen U-100Insulin Lispro | 22 | $7,063 |
| Advair HfaFluticasone Propion/Salmeterol | 13 | $5,621 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 193 | $4,788 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 45 | $4,450 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $175 | $104,13686 claims |
| PfizerEliquis, Nurtec Odt | $129 | $100,25190 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $561 | $79,15993 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $103 | $78,86168 claims |
| AbbVieVraylar | $387 | $70,34740 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $94 | $62,97796 claims |
| Boehringer IngelheimJardiance | $55 | $60,45659 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 94 primary care providers in Washington.
Other primary care in Montesano
- Abubakar Abdul-RahmanSeattle$27K
- Junghee CheLakewood$20K
- Margaret StewartMill Creek$14K
- Rhonna LeeSpokane$13K
- Joan ZimmerSpokane$12K
- Kimberly RianoOlympia$8K
- James PittmanSpokane$6K
- Shannon ZawilskiPuyallup$4K
- Sara AppudorayPuyallup$3K
- Lauren BerglindSilverdale$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.